Boston Scientific Corporation (NYSE:BSX) is a top healthcare equipment stock favored by hedge funds. Canaccord Genuity analyst reduced the price target to $109, offering a potential upside of over 46%. Bernstein analyst also revised the price target to $112, highlighting concerns about PFA competition and sales figures falling short of expectations.

The management of Boston Scientific Corporation (NYSE:BSX) implemented organizational changes, leading to revisions in estimates by analysts. The company specializes in medical devices for cardiovascular, endo-surgery, and neuro-modulation, operating through MedSurg and Cardiovascular segments. Despite concerns about competition and sales figures, the stock remains favored by analysts for its potential upside.

Investor concerns about competition and sales figures led to a reduction in the price target for Boston Scientific Corporation (NYSE:BSX) by analysts. Despite CEO attempts to ease concerns, U.S. EP sales for the quarter totaled $606 million, remaining flat year-on-year and 6% below consensus estimates. The company offers a range of medical devices for various specialties.

While Boston Scientific Corporation (NYSE:BSX) is seen as a potential investment, some believe AI stocks offer greater upside potential with less downside risk. For those seeking an undervalued AI stock benefiting from current trends, a free report on the best short-term AI stock is available. For more promising healthcare and industrial stocks, explore the links provided in the article.

Disclaimer: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Here is Why Boston Scientific Corporation (BSX) is Highly Favored by Hedge Funds